Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

The global generic pharmaceuticals contract manufacturing market is on an upward trajectory, with a CAGR of 6.15% from 2025 to 2033. As the industry shifts towards more cost-effective and high-quality ...

CDMOs and CROs share their most recent business highlights from the past twelve months on the oral solid dosage front.

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

Any company looking to work with a CDMO should begin by defining its own product’s development requirements. For example, a ...

Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

We never sold the combination in the countries where it's banned. Our exports were done only after getting valid product permissions from the State FDA and required export NOCs,' said Arvind Sharma, ...

Arvind Sharma, Managing Director told Moneycontrol that the exports were done only after getting valid product permissions from the State FDA and required export no-objection certificates ...